Lyell Immunopharma (LYEL) to Release Quarterly Earnings on Thursday

Lyell Immunopharma (NASDAQ:LYEL) is expected to announce its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($2.81) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:00 PM ET.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($2.89) EPS for the quarter, topping the consensus estimate of ($3.80) by $0.91. Lyell Immunopharma had a negative return on equity of 85.58% and a negative net margin of 552,328.31%.The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. On average, analysts expect Lyell Immunopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lyell Immunopharma Price Performance

Shares of NASDAQ:LYEL opened at $15.95 on Wednesday. The business’s 50-day moving average is $14.92 and its 200 day moving average is $11.54. Lyell Immunopharma has a 1 year low of $7.65 and a 1 year high of $30.00. The firm has a market capitalization of $306.42 million, a P/E ratio of -0.66 and a beta of -0.07.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Marshall Wace LLP acquired a new position in shares of Lyell Immunopharma in the second quarter valued at about $94,000. Bridgeway Capital Management LLC acquired a new position in shares of Lyell Immunopharma in the second quarter valued at about $159,000. Walleye Capital LLC acquired a new position in shares of Lyell Immunopharma in the second quarter valued at about $258,000. Orbimed Advisors LLC acquired a new position in shares of Lyell Immunopharma in the second quarter valued at about $457,000. Finally, AQR Capital Management LLC increased its holdings in shares of Lyell Immunopharma by 773.5% in the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock valued at $94,000 after purchasing an additional 154,327 shares during the period. 66.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently issued reports on LYEL shares. Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Monday, September 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $10.00.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.